Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - Royalty Pharma plc | d862976dex211.htm |
| EX-10.14 - EX-10.14 - Royalty Pharma plc | d862976dex1014.htm |
| EX-10.13 - EX-10.13 - Royalty Pharma plc | d862976dex1013.htm |
| EX-10.12 - EX-10.12 - Royalty Pharma plc | d862976dex1012.htm |
| EX-10.11 - EX-10.11 - Royalty Pharma plc | d862976dex1011.htm |
| EX-10.10 - EX-10.10 - Royalty Pharma plc | d862976dex1010.htm |
| EX-10.9 - EX-10.9 - Royalty Pharma plc | d862976dex109.htm |
| EX-10.2 - EX-10.2 - Royalty Pharma plc | d862976dex102.htm |
| EX-10.1 - EX-10.1 - Royalty Pharma plc | d862976dex101.htm |
| EX-5.1 - EX-5.1 - Royalty Pharma plc | d862976dex51.htm |
| S-1 - S-1 - Royalty Pharma plc | d862976ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 26, 2020 with respect to the consolidated financial statements of Royalty Pharma Investments and subsidiaries, in the Registration Statement (Form S-1) and related Prospectus of Royalty Pharma plc for the registration of shares of its common stock.
/s/ Ernst & Young
Dublin, Ireland
May 22, 2020